All tenders
75N93025C00039
IS TO DEVELOP PAN-INFLUENZA INHIBITORS TARGETING THE PA ENDONUCLEASE FROM THE VIRAL REPLICATION COMPLEX BY DEMONSTRATING PYRONARIDINE AS A VIABLE SINGLE DOSE TREATMENT FOR EBOLA INFECTION IN NON-HUMAN PRIMATES TO JUSTIFY FURTHER IN VIVO STUDIES FOR U
National Institutes of Health · United States
This contract has been awarded. Browse open opportunities
Time Left to Bid
Awarded
AwardedHealthcare & MedicalFederal
Basic information
- Reference number
- 75N93025C00039
- Issuing organization
- National Institutes of Health · Find award history →
- Government level
- Federal
- Solicitation type
- Healthcare & Medical
- Title
- IS TO DEVELOP PAN-INFLUENZA INHIBITORS TARGETING THE PA ENDONUCLEASE FROM THE VIRAL REPLICATION COMPLEX BY DEMONSTRATING PYRONARIDINE AS A VIABLE SINGLE DOSE TREATMENT FOR EBOLA INFECTION IN NON-HUMAN PRIMATES TO JUSTIFY FURTHER IN VIVO STUDIES FOR U
- Source
- USASpending (Federal)
- Source ID
- usa-75N93025C00039
Details
- Location
- United States
Description
IS TO DEVELOP PAN-INFLUENZA INHIBITORS TARGETING THE PA ENDONUCLEASE FROM THE VIRAL REPLICATION COMPLEX BY DEMONSTRATING PYRONARIDINE AS A VIABLE SINGLE DOSE TREATMENT FOR EBOLA INFECTION IN NON-HUMAN PRIMATES TO JUSTIFY FURTHER IN VIVO STUDIES FOR U Awarded to: COLLABORATIONS PHARMACEUTICALS, INC. Agency: Department of Health and Human Services Sub-agency: National Institutes of Health Award type: DEFINITIVE CONTRACT
Dates
- Publication
- 2025/09/29 12:00:00 AM UTC
- Closing date
- 2026/12/29 12:00:00 AM UTC
Estimated value
$2.0M USD
Classification
Normalized category
Healthcare & Medical